mEq/L). Patients in our cohort were followed for a median of 1.3 years (interquartile range 0.6-2.5). In our cohort, associations between higher potassium (>5.5 mEq/L) and higher mortality risk were observed in African-American and whites, but not Hispanic patients in models adjusted for case-mix and MICS covariates. While in Hispanics only, lower serum potassium (<3.6 mEq/L) levels were associated with higher mortality risk. Similar trends were observed for cardiovascular mortality. Conclusions: Higher potassium levels were associated with higher mortality risk in white and AfricanAmerican MHD patients, whereas lower potassium levels were associated with higher death risk in Hispanics. Further studies are needed to determine the underlying mechanisms for the differential association between potassium and mortality across race/ethnicity.
Racial and Ethnic Differences in Mortality Associated with Serum Potassium in a Large Hemodialysis Cohort
ruption in homeostasis and subsequent hyperkalemia are commonly observed, and the latter may be ameliorated by a reduction of potassium intake and utilization of potassium-lowering medications that augment potassium excretion via the gastrointestinal tract [2] . Despite these interventions, hyperkalemia is more frequently observed in chronic kidney disease (CKD) patients compared to the non-CKD population [3] . Dissecting the potassiummortality relationship is of particular importance, given that maintenance hemodialysis (MHD) patients have an exceedingly high cardiovascular mortality (40% of all deaths) largely due to sudden cardiac arrest, and hyperkalemia may lead to life-threatening cardiac arrhythmias and higher death risk in this population [4] [5] [6] . Several studies suggest that there may be differences in potassium homeostasis across racial/ethnic groups. For example, prior data has shown that dietary potassium intake and/or urinary potassium excretion used to determine serum potassium levels differs in whites and African-Americans [7, 8] . It is also well-established that there are racial/ethnic differences in the mortality of maintenance dialysis patients, such that African-Americans have a survival advantage compared to white patients, particularly in those of middle and older age groups [9] [10] [11] . While there have been fewer studies in Hispanic MHD patients, emerging data suggests that Hispanics also have a survival advantage compared to non-Hispanic whites and African-Americans [11] [12] [13] , even after accounting for differences in socioeconomic factors and comorbid conditions [14] . Whereas epidemiologic data show that serum potassium levels differ across race/ethnicity in the general population, there has been no prior study on the distribution of serum potassium levels and their associations with mortality across race/ethnicity in MHD patients [8] . Therefore, we examined racial/ethnic differences in serum potassium levels across whites, AfricanAmericans, and Hispanics in a contemporary cohort of incident MHD patients who were followed up to 5 years. Moreover, we examined whether there is a differential association between serum potassium level and mortality risk across these racial/ethnic groups.
Materials and Methods

Source Population
We conducted analyses using administrative data from all incident hemodialysis (HD) patients who initiated dialysis from January 1, 2007 to December 31, 2011 in the outpatient facilities of the large dialysis organization. From January 2007 to December 2011, there were 208,820 patients who initiated dialysis treatment.
After excluding patients less than 18 years of age, patients who received less than 60 days of dialysis treatment, or were ever treated with any other dialysis modality, 133,156 incident HD patients remained.
After excluding patients who were not of white, AfricanAmerican, and Hispanic race/ethnicity and those with missing baseline serum potassium information, the final study population consisted of 102,241 incident HD patients (online suppl. Appendix- Fig. S1 ; for all online suppl. material, see www.karger.com/ doi/10.1159/000475997). The study was approved by the International Review Committees of the University of California Irvine, Los Angeles Biomedical Research Institute at Harbor-UCLA, and the University of Washington. Given the large sample size, anonymity of the patients studied, and nonintrusive nature of the research, the requirement for written consent was exempted.
Socio-Demographic and Clinical Measures
Over 99% of the cohort had information on race/ethnicity which was based on "self-identified" data based on definitions of the US Census Bureau and guidance of US Office of Management and Budget. Information on primary insurance, initial vascular access type, and the presence of comorbidities at baseline were obtained from the large dialysis organization database. The following coexisting comorbidities were also considered: diabetes mellitus (DM), hypertension, congestive heart disease (CHF), atherosclerotic heart disease, other cardiac disease (pericarditis and cardiac arrhythmia), cerebrovascular disease, chronic obstructive pulmonary disease, liver disease, dyslipidemia, malignancy, human immunodeficiency virus antibody positive status, substance abuse, and alcohol abuse.
Laboratory and Clinical Measures
Blood samples were drawn using standardized techniques in all dialysis clinics and were transported to a central laboratory in Deland, Florida, typically within 24 h of collection. Most laboratory values were measured monthly, including serum potassium, creatinine, albumin, hemoglobin, platelet count, peripheral white blood cell count (WBC), lymphocyte percentage, total iron binding capacity (TIBC), calcium, phosphorus, bicarbonate, blood urea nitrogen (BUN), and alkaline phosphatase. Serum intact parathyroid hormone (iPTH), and ferritin levels were usually measured at least once during each calendar quarter. Most blood samples were collected before HD, except for post-dialysis BUN to calculate urea kinetics. The normalized protein catabolic rate (nPCR) was measured monthly as an indicator of daily protein intake. Dialysis dose was estimated by single pool Kt/V (spKt/V) using the urea kinetic model. The average serum urea concentrations during the collection were assumed to be 90% of the pre-dialysis concentration according to the Daugirdas approach, and thus residual renal function was calculated as follows [15] .
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To account for the competing risk of transplantation across race/ethnicity in sensitivity analyses, we conducted Fine and Gray competing risk regression to estimate the sub-hazard ratios of death risk [18] . To address potential residual confounding on the basis of residual renal function, sensitivity analyses that additionally adjusted for residual urine volume were conducted. While there were no missing data for age, data for sex, race/ethnicity, and comorbidities, missing covariates <5% at study entry were imputed by mean or median values as appropriate. All analyses were conducted using STATA MP version 13.1 (StataCorp, College Station, TX, USA).
Results
Study Population Description
The mean ± SD age of the overall cohort was 63 ± 15 years and the mean ± SD serum potassium level was 4.4 ± 0.5 mEq/L. The median duration of follow-up was 1.3 years (25th-75th percentile, 0.6-2.5 years). The crude all-cause mortality rate of the overall cohort was 139 death events per 1,000 patient-years of follow-up (95% CI 138-141 death events per 1,000 patient-years). Differences in serum potassium levels were evident across racial/ethnic groups (p < 0.001), as Hispanics tended to have the highest baseline serum potassium levels (mean ± SD: 4.58 ± 0.55 mEq/L), whereas AfricanAmericans had the lowest levels (mean ± SD: 4.31 ± 0.50 mEq/L; Fig. 1 ). Baseline characteristics of the cohort stratified by race/ethnicity and baseline serum potassium level are presented in Table 1 . Across all racial/eth-HD weights that were measured every HD session. Seated pre-HD blood pressure (BP) values were measured every HD session. The median weekly erythropoiesis stimulating agent (ESA) dose was calculated by dividing the cumulative quarterly ESA dose by the total number of HD treatments over a 91-day period, and then multiplying the per-treatment dose by the number of median treatments per week. To minimize measurement variability, all repeated measures for each patient during any given patient quarter (i.e., 91-day intervals) were averaged, and summary estimates used in all analyses. The 91-day averaged values during the first patient quarter of dialysis treatment were used as baseline values.
Outcome Measures
The recorded causes of death were obtained from the large dialysis organization data records, and cardiovascular death was defined as death due to cardiovascular reasons, including acute myocardial infarction, cardiac arrest, heart failure, cerebrovascular accident, and other cardiac disease. Patients were followed from 91 days from the start of dialysis to death, kidney transplantation, transfer to a non-affiliated dialysis unit, recovery of renal function, dialysis discontinuation or end of the study period (December 31, 2011).
Statistical Methods
Baseline characteristics across race/ethnicity groups were summarized as proportions, mean ± SD, or medians (interquartile ranges) depending on data type. We used logistic regression to estimate the association between clinical characteristics with the likelihood of hyperkalemia (serum potassium >5.0 vs. >3.6 to ≤ 5.0 mEq/L) or hypokalemia ( ≤ 3.6 vs. >3.6 to ≤ 5.0 mEq/L) across racial/ethnic groups.
We examined the association between serum potassium as a continuous variable using restricted cubic spline analyses (with knots at the 33rd and 66th percentile for each group's potassium distribution) and all-cause mortality across racial/ethnic groups using Cox proportional hazards model. We then stratified patients according to the 6 groups of baseline serum potassium representing a combination of clinical reference ranges and the distribution of our cohort ( ≤ 3.6, >3.6 to ≤ 4.0, >4.0 to ≤ 4.5, >4.5 to ≤ 5.0, >5.0 to ≤ 5.5, and >5.5 mEq/L) and the 3 racial/ethnic groups (i.e., total of 18 categories), and examined their associations with mortality. We also separately examined the association of hyperkalemia and hypokalemia (reference: serum potassium >3.6 to ≤ 5.0 mEq/L) with all-cause and cardiovascular mortality in the overall cohort and across clinically relevant subgroups stratified by race/ethnicity, and p values for interactions between serum potassium and subgroup covariates were assessed. Proportional hazards assumptions were assessed by graphical methods.
For each analysis, 3 levels of multivariable adjustment were used: (1) unadjusted models that included the main predictor, serum potassium; (2) case-mix adjusted models that included covariates in the unadjusted model as well as age, sex, DM, primary insurance, initial vascular access type, spKt/V, HD treatment time, UF, and cardiovascular risk factors including pre-HD systolic BP, pre-HD diastolic BP, body mass index (BMI), and previously mentioned comorbidities; (3) case-mix + malnutrition-inflammation cachexia syndrome (MICS) adjusted models that included covariates in the case-mix model as well as 12 surrogates of nutritional and/or inflammatory status: albumin, hemoglobin, peripheral WBC, lymphocyte percentage, ferritin, TIBC, calcium, phosphorus, bicarbonate, BUN, iPTH, nPCR, and ESA dose. Table 2 shows the association of clinical characteristics with the likelihood of hyperkalemia (reference: serum potassium >3.6 to ≤ 5.0 mEq/L) across racial/ethnic groups in case-mix + MICS adjusted logistic regression models. Across all racial/ethnic groups, older age, higher baseline spKt/V, AV fistula access, and higher baseline BMI were associated with lower likelihood of hyperkalemia. Higher levels of nutritional status markers (higher albumin, phosphorus, and nic groups, patients in the highest serum potassium category were more likely to be younger and less likely to use Medicare as their primary insurance. They were also more likely to have CHF and higher nPCR, albumin, creatinine, platelet, iPTH, phosphorus, BUN, pre-HD SBP and DBP, and UF levels; they had lower spKt/V and bicarbonate levels compared to those in the lowest potassium category.
Clinical Characteristics Associated with Potassium Level across Racial/Ethnic Groups
In logistic regression analyses in the overall cohort, compared to white patients, African-Americans had a 42% lower odds of hyperkalemia (OR 0.58, 95% CI 0.55- Table S1 ). There was no association between HD treatment time and hypokalemia for any racial/ethnic group.
Serum Potassium and Mortality across Racial/ Ethnic Groups
In case-mix + MICS adjusted cubic spline models, there was a J-shaped relationship between serum potassium and all-cause mortality in whites and AfricanAmericans, such that higher serum potassium levels were associated with higher mortality risk, while lower serum potassium levels had no significant association with mortality ( Table 3 ). In whites, serum potassium levels >4.5 mEq/L were associated with incrementally higher mortality risk in case-mix + MICS adjusted models ( Fig. 2 a) 30 ] for serum potassium levels >4.5 to ≤ 5.0, >5.0 to ≤ 5.5, and >5.5 mEq/L, respectively. African-Americans also demonstrated an association between higher serum potassium level and higher mortality risk, albeit at a higher serum potassium threshold of >5.5 mEq/L: HR (95% CI) 1.43 (1.21-1.70) ( Table 3 ).
Conversely, among Hispanics, lower serum potassium levels were associated with higher mortality, whereas higher serum potassium levels had no association with mortality in the case-mix + MICS adjusted models ( Fig. 2 a) . In categorical analyses, only very low serum potassium levels ( ≤ 3.6 mEq/L) were significantly associated with higher mortality risk in Hispanics: HR (95% CI) 1.36 (1.15-1.62) ( Table 3 ) . These trends were similar in the case-mix + MICS adjusted cubic spline models (online suppl. Appendix- Fig. S2 ). While serum potassium levels >5.5 mEq/L trended towards higher cardiovascular mortality risk in whites and African-Americans, they were associated with lower cardiovascular mortality risk in Hispanics, although this was not statistically significant ( Fig. 2 b) . Figure 3 shows the association between 18 categories of race/ethnicity and baseline serum potassium level with all-cause mortality. Compared to Hispanics with serum potassium levels >4.0 to ≤ 4.5 mEq/L as the reference category, all potassium categories were associated with higher mortality risk amongst whites in case-mix + MICS adjusted models. All potassium categories were associated with higher mortality risk amongst AfricanAmericans compared to the reference group. Amongst Hispanics, patients with serum potassium >4.5 mEq/L had similar mortality risk compared to the reference group, whereas those with serum potassium ≤ 3.6 mEq/L had a higher mortality risk. Similar observations were observed after taking into consideration the impact of kidney transplantation as a competing event, in casemix + MICS adjusted models (online suppl. Appendix- Fig. S3 ). Figure 4 shows the case-mix + MICS adjusted associations between hyperkalemia and all-cause mortality (reference: potassium levels >3.6 to ≤ 5.0 mEq/L) across a priori selected subgroups stratified by race/ethnicity. Within white patients, there was effect modification on the basis of Medicare insurance type ( p -interaction = 0.007), and hypertension comorbidity ( p -interaction = 0.004). There was no significant effect modification across subgroups among African-American or Hispanic patients. Similar associations of hypokalemia with mortality within each racial-ethnic group were persistent across most of all subgroups. In white patients, there was a significant effect modification by diabetes comorbidity ( p -interaction = 0.001) and in African-American by hypertension comorbidity ( p -interaction = 0.025). In both Hispanic and white patients, significant effect modification on the association of hypokalemia with mortality was observed ( p -interaction ≤ 0.001 for each; online suppl. Appendix- Fig.  S4 ).
Potassium and Mortality across Subgroups
To account for confounding on the basis of residual renal function, we incrementally adjusted the baseline urine volume within the case-mix + MICS adjusted models in a subcohort of 35,910 patients who had residual renal function data during the first patient quarter in sensitivity analyses. Although the potassium-mortality associations were attenuated across all racial/ethnic groups, trends of higher serum potassium level and higher mor-
Discussion
In this study, we examined the differences in the relationship between serum potassium level and all-cause mortality across 3 racial/ethnic groups of non-Hispanic whites, African-Americans, and Hispanics in a contemporary cohort of over 100,000 incident HD patients who were followed for up to 5 years. We found that Hispanic HD patients tended to be more hyperkalemic than whites and African-Americans. We also observed that hyperkalemia was associated with higher mortality risk in whites and African-American HD patients, but not in Hispanics. Furthermore, in analyses that concurrently examined the association of serum potassium and race/ ethnicity with mortality, compared with Hispanics with Case-mix + MICS models adjusted for age, sex, diabetes mellitus, primary insurance, vascular access type, spKt/V, HD treatment time, UF, and cardiovascular risk factors including pre-HD systolic BP, pre-HD diastolic BP, BMI, comorbidities, 13 surrogates of nutritional and/or inflammatory status (albumin, hemoglobin, peripheral WBC, lymphocyte percentage, ferritin, TIBC, calcium, phosphorus, bicarbonate, BUN, iPTH, nPCR, and ESA dose). n, number; CV, cardiovascular; HR, hazard ratio. HD, hemodialysis; UF, ultrafiltration; BMI, body mass index; TIBC, total iron binding capacity; BUN, blood urea nitrogen; iPTH, intact parathyroid hormone; nPCR, normalized protein catabolic rate; ESA, erythropoiesis stimulating agent. moderate range serum potassium levels (>4 to 4.5 mEq/L), whites and African-Americans across all potassium categories had higher mortality risk, whereas Hispanics with serum potassium levels ≤ 3.6 mEq/L had higher mortality risk.
To our knowledge, ours is the first study to examine the differences in serum potassium distribution and associations with mortality in HD patients across racial/ ethnic subgroups, including African-Americans, whites, and Hispanics. To date, there has been one study that has Association between serum potassium categories and allcause mortality ( a ) and cardiovascular mortality ( b ) across race/ ethnicity in case-mix + MICS models (reference: serum potassium >4.0 to 4.5 mEq/L). Case-mix + MICS models adjusted for age, sex, DM, primary insurance, vascular access type, spKt/V, HD treatment time, UF, and cardiovascular risk factors including pre-HD systolic BP, pre-HD diastolic BP, BMI, comorbidities, 13 surrogates of nutritional and/or inflammatory status (albumin, hemoglobin, peripheral WBC, lymphocyte percentage, ferritin, TIBC, calcium, phosphorus, bicarbonate, BUN, iPTH, nPCR, and ESA dose). DM, diabetes mellitus; HD, hemodialysis; UF, ultrafiltration; BMI, body mass index; TIBC, total iron binding capacity; BUN, blood urea nitrogen; iPTH, intact parathyroid hormone; nPCR, normalized protein catabolic rate; ESA, erythropoiesis stimulating agent. Fig. 3 . Association between 18 groups of race/ethnicity and baseline serum potassium with all-cause mortality in case-mix + MICS models (reference: Hispanics with serum potassium >4.0 to 4.5 mEq/L). Casemix + MICS models adjusted for age, sex, DM, primary insurance, vascular access type, spKt/V, HD treatment time, UF, and cardiovascular risk factors including pre-HD systolic BP, pre-HD diastolic BP, BMI, comorbidities, 13 surrogates of nutritional and/or inflammatory status (albumin, hemoglobin, peripheral WBC, lymphocyte percentage, ferritin, TIBC, calcium, phosphorus, bicarbonate, BUN, iPTH, nPCR, and ESA dose). DM, diabetes mellitus; HD, hemodialysis; UF, ultrafiltration; BMI, body mass index; TIBC, total iron binding capacity; BUN, blood urea nitrogen; iPTH, intact parathyroid hormone; nPCR, normalized protein catabolic rate; ESA, erythropoiesis stimulating agent. examined the association between serum potassium levels and mortality across race in pre-dialysis CKD patients [19] . In one study by Hayes et al. [19] , white CKD patients had higher baseline serum potassium levels compared to African-Americans, and associations of hyperkalemia with higher mortality risk were observed in white patients only, while associations of hypokalemia with higher mortality were found in both black and white patients. Notably, this study did not include dialysis patients or distinguish between Hispanics vs. non-Hispanics. Another previous study has also examined associations between potassium and mortality in pre-dialysis CKD patients, and found that African-Americans had significantly lower levels of serum potassium. However, this study did not examine effect modification by race/ethnicity [20] . While the sources of racial/ethnic differences in serum potassium levels remains unclear, it is possible that this may be explained by dietary differences across these groups. According to the National Health and Nutrition Examination Survey data from 1999 to 2002, AfricanAmericans tended to consume less fruits and vegetables and more meat than whites and Hispanics, which may explain the lower serum potassium levels found in this racial/ethnic subgroup [21, 22] . Despite differences ob- served in serum potassium levels, there were no significant differences between Hispanics and whites in the consumption of fruit and vegetables [21] . However, the primary sources of potassium intake in Hispanics were from eggs, whereas in whites this was obtained from legumes, nuts, seeds, dairy products, and beverages [23] . In another study by Kalantar-Zadeh et al. [24] , characterizing food consumption in patients initiating HD, it was found that, after receiving dietary instructions, patients independently modified their diet and limited potassium intake to maintain appropriate serum potassium levels. Although Hispanics and non-Hispanics had identical adherence to potassium restriction recommendations [25] , the overall dietary modifications may have been more challenging in Hispanic patients due to the impact of cultural differences in food choice [26] . Due to data limitations, we were unable to determine if the higher serum potassium distribution in Hispanics was due to higher intake of fruits and vegetables related to cultural background. Differences in serum potassium levels may also be impacted by potassium homeostasis. It is well established that African-Americans have lower serum potassium levels that may be attributed to a blunted natriuretic response and lower Na + -K + ATPase activity [27, 28] . These may also be related to differences in intracellular potassium content, RAAS activity, and/or intestinal potassium transport. However, since we cannot measure the total body potassium or intracellular potassium in our cohort, we can only speculate what lower serum potassium levels in African-American HD patients represents, and we cannot conclude what effect this might have on membrane potential and excitability, and ultimately on clinical events, including mortality. Increases in excretion or transcellular shifts and alterations in Na + -K + ATPase activity may be additionally associated with diabetic comorbid conditions [29] . In our cohort, African-Americans had a significantly higher prevalence of diabetes comorbidity. Although these mechanistic differences may explain why African-Americans had lower levels of serum potassium overall, in analyses adjusted for diabetes as well as across diabetes strata, we did not see significant differences in the associations of hyperkalemia with mortality outcomes.
Conversely, in our cohort Hispanics had the highest prevalence of diabetes comorbidity, but had the highest levels of baseline serum potassium. Associations of hyperkalemia with mortality were attenuated in Hispanic diabetic patients; however, there were no significant interactions between race and diabetes in the associations of hyperkalemia with mortality. To date, there is a lack of data examining differences in biological mechanisms of potassium levels in Hispanic vs. non-Hispanic patients. Additional information on factors that affect membrane excitability in this racial/ethnic group are needed to better understand if these factors can explain differences in mortality outcomes associated with the same serum potassium levels.
Racial/ethnic genetic differences may explain the differential association between hyperkalemia and mortality risk across racial/ethnic groups. Indeed, a mutational analysis study conducted in non-CKD patients has identified distinct cardiac potassium channel variants related to higher risk of sudden cardiac death across racial/ethnic groups, and further study in the kidney disease population is needed [30] .
Patients who chronically consume a high potassium diet may develop potassium tolerance, and they may no longer be susceptible to the adverse sequelae of hyperkalemia. In a large national cohort study of veterans, patients with CKD had a higher frequency of hyperkalemic events as compared with non-CKD patients. However, the mortality predictability of hyperkalemia was inversely related to the CKD stage, presumably due to the development of potassium tolerance and less subsequent susceptibility to cardiac toxicity due to chronic exposure to high potassium levels [3] . It is possible that Hispanic patients who are exposed to a high potassium diet over a lifetime may develop such potassium tolerance and thereby have a lower risk of mortality while in the hyperkalemic state. It may also explain why Hispanic patients with lower serum potassium level have a higher mortality risk, since it may be a departure from a normative healthy state.
A systematic review has shown that Hispanics have a lower cardiovascular mortality than non-Hispanic whites due to the differences in diet patterns that improve the endothelial function and physical activity that modifies cardiovascular risk factors [31] . Although Hispanics have a greater prevalence of cardiovascular risk factors such as diabetes, abdominal obesity, and hypertriglyceridemia [32] , several studies have demonstrated that Hispanics with CKD and ESRD had a lower incidence of cardiovascular events compared with non-Hispanic whites [12, 33] . It is possible that fewer cardiovascular events account for lower cardiovascular mortality in Hispanics with higher serum potassium, but further study is needed to determine the mechanism. To our knowledge, this is the first study to evaluate racial/ethnic differences in the relationship between serum potassium levels and mortality in a large nationally representative, contemporary cohort of incident HD patients with detailed capture of sociodemographic, comorbidity, and laboratory data. However, our study has several limitations. First, Hispanics may be heterogeneous in terms of cultural backgrounds and countries of origin, which may have implications on serum potassium concentrations [34, 35] . We were unable to distinguish Hispanic subpopulations, which may be white or black race. It has been shown that Hispanic subgroups in the US originating from different countries including Mexico, the Caribbean, and Central and South America have differences in the consumption of fruits, vegetables, meat, and fats [36] . Potassium intake also differed according to individual and/or neighboring socioeconomic status [37] . We did not have data on dietary potassium intake. In addition, information on residual renal function was only available for one third of our cohort. Analyses adjusting for potential confounding due to residual renal function may be inherent to selection biases, and future studies investigating the impact of residual renal function on the racial/ethnic differences in serum potassium mortality associations are warranted. We also lacked data on certain dialysis treatment characteristics that may influence serum potassium concentrations such as use of RAAS inhibitors and diuretics and dialysate potassium concentration. While one observational study has shown that higher dialysate potassium bath was associated with higher mortality risk in HD patients with hyperkalemia [4] , another study showed no difference in cardiac death between dialysate potassium bath and serum potassium levels even amongst hyperkalemic HD patients [38] . Given the observational nature of this cohort analysis, our study is limited to adjusting for confounders that were measured in the dataset. We thereby cannot exclude the possibility of potential residual confounding.
In conclusion, our study has shown that Hispanic HD patients tend to have higher serum potassium levels as compared to African-American and white HD patients. While African-Americans and whites with higher potassium levels experienced higher death risk, this was not observed in Hispanic HD patients. Potential mechanisms underlying differences in serum potassium distributions and associations with mortality may be related to socio-cultural influences such as high potassium tolerance related to a chronically high potassium diet, or potassium adaptation related to racial/ethnic genetic differences. Further studies are needed to determine the possible causal mechanisms underlying the survival advantage observed in hyperkalemic Hispanic HD patients.
